Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyureaAbdulraheem Yacoub, Ronald Hoffman, John Mascarenhas et al.|Blood|2019Cited by 175
Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)John Mascarenhas, Robert S. Hoffman, Heidi Kosiorek et al.|Blood|2018Cited by 45
Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III TrialRuben A. Mesa, Amylou C. Dueck, Heidi Kosiorek et al.|Blood|2018Cited by 12
Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm–blast phaseXiaoli Wang, Ronald Hoffman, Erin McGovern et al.|JCI Insight|2022Cited by 6